Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03132922 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03132922 · ClinicalTrials.gov record · last posted 2026-06-04

MAGE-A4ᶜ¹º³²T for Multi-Tumor

StatusActive, Not Recruiting
PhasePhase 1
Started2017-05-15
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. This study has a substudy component that will investigate the safety and tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10 subjects.

Amendment record 29 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 29 times since 2017-04-25; most recent amendment 2026-05-08. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2021-10-04
Status change Recruiting→Active, Not Recruitingv25
2017-05-02
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT03132922
Lead Sponsor USWM CT, LLC
Conditions Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma +2 more
Enrollment 71 participants
Start Date 2017-05-15
Primary Completion 2022-12-27 (estimated)
Study Completion 2032-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-04